Anupam Rasayan India Ltd has successfully executed a significant External Commercial Borrowing (ECB) facility agreement worth USD 30,000,000 with Axis Bank Limited, IBU GIFT City and other syndicated lenders. The facility agreement, initially executed on 14 February 2026, became effective from 19 February 2026 following amendments implemented by the Reserve Bank of India.

ECB Facility Details

The company disclosed comprehensive details of the ECB facility under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The facility represents a term loan arrangement designed to support the company's strategic expansion plans.

Purpose and Strategic Acquisition

The proceeds from the ECB facility will be utilized by the company for partially funding a strategic acquisition. Specifically, the funds will support the acquisition of the entire shareholding of Monitchem Kansas S.à r.l. and an intragroup loan receivable owed by Kansas HoldCo 1, Inc. to CABB GmbH, collectively referred to as the "Proposed Acquisition," along with associated costs.

Security Arrangements

The ECB facility will be secured through multiple security instruments to be executed between the company and Axis Trustee Services Limited as the ECB Security Agent:

Regulatory Compliance and Documentation Correction

The company also corrected an earlier intimation regarding the execution dates of related agreements. The Share Subscription Agreement between Doriath S.a.r.l. and Batam S.a.r.l., along with the assignment agreement between Doriath and the company, were executed on 14 February 2026, not 12 February 2026 as previously stated.

The facility agreement incorporates amendments implemented by the Reserve Bank of India through the Foreign Exchange Management (Borrowing and Lending) (First Amendment) Regulations, 2026, published in the official gazette on February 16, 2026.

Terms and Conditions

The ECB facility agreement includes standard corporate governance constraints through covenants covering change of control, share issuance, rights amendments, and distributions. The agreement does not grant the lender any rights to appoint directors or observers to the company's board. Negative pledge provisions restrict security creation except for permitted security, including pari passu security supporting specified permitted pari passu indebtedness.

The funding under the ECB facility is subject to customary conditions precedent, including execution of financing and security documents, corporate authorizations, and completion of security perfection requirements. The company must complete charge registration with the Registrar of Companies and necessary filings with the Authorized Dealer Bank within prescribed timelines.

Source:

Anupam Rasayan India Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025, following a board meeting held on February 14, 2026. The specialty chemicals manufacturer released comprehensive standalone and consolidated financial statements under Regulation 33 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Exceptional Q3 FY26 Performance

The company demonstrated remarkable growth in the third quarter, with standalone revenue from operations reaching ₹4,013.67 million, representing an outstanding 89% year-on-year increase. Total revenue including other income stood at ₹4,063.20 million for the quarter.

Nine-Month Performance Highlights

The nine-month performance showed exceptional momentum across standalone operations. Revenue from operations for the nine months reached ₹13,049.87 million with remarkable 130% year-on-year growth, while profit after tax surged to ₹1,190.13 million, marking a substantial 244% increase.

Consolidated Financial Performance

On a consolidated basis, the company maintained strong growth trajectory with revenue from operations of ₹5,124.47 million in Q3 FY26 compared to ₹3,901.40 million in the previous year. Consolidated profit after tax reached ₹605.93 million for the quarter, while nine-month consolidated revenue touched ₹17,296.72 million.

Management Insights from Earnings Call

During the earnings call held on February 14, 2026, Managing Director Anand Desai highlighted the strong performance driven by scale-up of commercial molecules and improved capacity utilization. The company's revenue mix is well diversified across Agro, Pharma, Personal Care, and Performance Material segments, with Pharma contributing 19% of sales for 9M FY26.

Strategic Acquisition and Expansion

The company announced a definitive agreement to acquire 100% equity in Jayhawk Fine Chemicals, a US-based specialty chemicals company from the CABB Group. This acquisition will provide direct onshore manufacturing presence in the US, enhancing engagement with multinational customers and access to high-value markets including semiconductors, automotive, EV, Pharma, aviation, and electronics.

Pipeline and Development Focus

Chief Executive Officer Gopal Agrawal emphasized the company's strong pipeline with 65 plus molecules across R&D and pilot stages. The Pharma segment alone has more than 30 molecules under development, while the Polymer and Electronic Material vertical has 35 plus molecules in various stages of development.

Regulatory Compliance and Documentation

The financial results were prepared in accordance with Indian Accounting Standard 34 (Ind AS 34) for Interim Financial Reporting under Section 133 of the Companies Act, 2013. The earnings call transcript was submitted to stock exchanges under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, and is available on the company website at www.anupamrasayan.com .